ANZUP Mini ASM 2021
ANZUP 2021 GU Malignancies Prostate
- ANZUP Mini ASM 2021: Convergence of Machine Learning and Genomics for Precision Cancer Medicine in Genitourinary Cancers and Beyond
- ANZUP Mini ASM 2021: How MRI Became the Mainstay of Active Surveillance
- ANZUP Mini ASM 2021: The Trials and Tribulations of Managing Men With Metastatic Hormone-Sensitive Prostate Cancer
- ANZUP Mini ASM 2021: An Update On The ANZUP Consumer Advisory Panel (CAP)
- ANZUP Mini ASM 2021: Trials in Prostate Cancer: From Initial Diagnosis To Salvage Therapy in Localized Disease and Trials in the Metastatic Prostate Cancer Setting
ANZUP 2021 GU Malignancies Non-Prostate
- ANZUP Mini ASM 2021: Molecular Subtypes in MIBC – Moving Toward Better Patient Selection for Treatment
- ANZUP Mini ASM 2021: Evolving Treatment Landscape for Metastatic Urothelial Cancer
- ANZUP Mini ASM 2021: Cross-Fire Debate: Waiting for Overall Survival Data: We May Wait
- ANZUP Mini ASM 2021: Cross-Fire Debate: Waiting for Overall Survival Data Is Both Unnecessary and Potentially Harmful
- ANZUP Mini ASM 2021: Wishful Thinking - Optimal Therapy for Systemic Therapy in Upper Tract Urothelial Carcinoma